

DAFTAR PUSTAKA

- [1] J. S. Brown, S. R. Amend, R. H. Austin, R. A. Gatenby, E. U. Hammarlund, and K. J. Pienta, “Updating the Definition of Cancer,” *Mol. Cancer Res.*, vol. 21, no. 11, pp. 1142–1147, Nov. 2023, doi: 10.1158/1541-7786.MCR-23-0411.
- [2] “Cancer.” Accessed: Jan. 07, 2024. [Online]. Available: <https://www.who.int/news-room/fact-sheets/detail/cancer>
- [3] “Global cancer burden growing, amidst mounting need for services.” Accessed: Jan. 07, 2024. [Online]. Available: <https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing-amidst-mounting-need-for-services>
- [4] The Global Cancer Observatory, “Cancer Today: Indonesia Fact Sheets 2022,” International Agency for Research on Cancer, Feb. 2024.
- [5] L. Pecorino, *Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics*. Oxford University Press, 2021.
- [6] M. Sekhoacha, K. Riet, P. Motloun, L. Gumenu, A. Adegoke, and S. Mashele, “Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches,” *Molecules*, vol. 27, no. 17, p. 5730, Sep. 2022, doi: 10.3390/molecules27175730.
- [7] Z. Chen, M. M. Dominello, M. C. Joiner, and J. W. Burmeister, “Proton versus photon radiation therapy: A clinical review,” *Front. Oncol.*, vol. 13, p. 1133909, Mar. 2023, doi: 10.3389/fonc.2023.1133909.
- [8] V. Chandraraj, D. B. R. R. Buchapudi, R. Manickam, D. S., and K. M. Ganesh, “Physical characteristics of photon and electron beams from a radiotherapy accelerator,” *Int. J. Med. Res. Rev.*, vol. 4, pp. 1178–1188, Jul. 2016, doi: 10.17511/ijmrr.2016.i07.18.
- [9] X. Tian, K. Liu, Y. Hou, J. Cheng, and J. Zhang, “The evolution of proton beam therapy: Current and future status,” *Mol. Clin. Oncol.*, vol. 8, no. 1, pp. 15–21, Jan. 2018, doi: 10.3892/mco.2017.1499.
- [10] Y.-Y. Wu and K.-H. Fan, “Proton therapy for prostate cancer: current state and future perspectives,” *Br. J. Radiol.*, vol. 95, no. 1131, p. 20210670, Mar. 2022, doi: 10.1259/bjr.20210670.



- [11] T. Furuta and T. Sato, "Medical application of particle and heavy ion transport code system PHITS," *Radiol. Phys. Technol.*, vol. 14, no. 3, pp. 215–225, Sep. 2021, doi: 10.1007/s12194-021-00628-0.
- [12] T. Sato, K. Niita, N. Matsuda, S. Hashimoto, Y. Iwamoto, T. Furuta, S. Noda, T. Ogawa, H. Iwase, H. Nakashima, T. Fukahori, K. Okumura, T. Kai, S. Chiba, and L. Sihver, "Overview of particle and heavy ion transport code system PHITS," *Ann. Nucl. Energy*, vol. 82, pp. 110–115, Aug. 2015, doi: 10.1016/j.anucene.2014.08.023.
- [13] S. Yonai, N. Matsufuji, and K. Akahane, "Monte Carlo study of out-of-field exposure in carbon-ion radiotherapy with a passive beam: organ doses in prostate cancer treatment," *Phys. Med.*, vol. 51, pp. 48–55, 2018.
- [14] M. Ilham, "Analisis dosis dan waktu iradiasi terapi proton pada kanker serviks menggunakan PHITS.pdf," Skripsi S-1, Universitas Gadjah Mada, Yogyakarta, 2022.
- [15] W. Cao, G. J. Lim, Y. Li, X. R. Zhu, and X. Zhang, "Improved Beam Angle Arrangement in Intensity Modulated Proton Therapy Treatment Planning for Localized Prostate Cancer," *Cancers*, vol. 7, no. 2, Art. no. 2, Jun. 2015, doi: 10.3390/cancers7020574.
- [16] C. H. Lee, O. Akin-Olugbade, and A. Kirschenbaum, "Overview of Prostate Anatomy, Histology, and Pathology," *Endocrinol. Metab. Clin. North Am.*, vol. 40, no. 3, pp. 565–575, Sep. 2011, doi: 10.1016/j.ecl.2011.05.012.
- [17] R. Toivanen and M. M. Shen, "Prostate organogenesis: tissue induction, hormonal regulation and cell type specification," *Dev. Camb. Engl.*, vol. 144, no. 8, pp. 1382–1398, Apr. 2017, doi: 10.1242/dev.148270.
- [18] M. W. Dunn and M. W. Kazer, "Prostate Cancer Overview," *Semin. Oncol. Nurs.*, vol. 27, no. 4, pp. 241–250, Nov. 2011, doi: 10.1016/j.soncn.2011.07.002.
- [19] S. R. Bott and K. L. Ng, Eds., *Prostate Cancer*. Brisbane (AU): Exon Publications, 2021. Accessed: Oct. 12, 2023. [Online]. Available: <http://www.ncbi.nlm.nih.gov/books/NBK571325/>
- [20] A. Żurowska, R. Pęksa, M. Bieńkowski, K. Skrobisz, M. Sowa, M. Matuszewski, W. Biernat, and E. Szurowska, "Prostate Cancer and Its Mimics—A Pictorial Review," *Cancers*, vol. 15, no. 14, Art. no. 14, Jan. 2023, doi: 10.3390/cancers15143682.



- [21] N. Borley and M. R. Feneley, "Prostate cancer: diagnosis and staging," *Asian J. Androl.*, vol. 11, no. 1, pp. 74–80, Jan. 2009, doi: 10.1038/aja.2008.19.
- [22] C. M. Bryant, R. H. Henderson, R. C. Nichols, W. M. Mendenhall, B. S. Hoppe, C. E. Vargas, T. B. Daniels, C. R. Choo, R. R. Parikh, H. Giap, J. D. Slater, N. Vapiwala, W. Barrett, A. Nanda, M. V. Mishra, S. Choi, J. J. Liao, and N. P. Mendenhall, "Consensus Statement on Proton Therapy for Prostate Cancer," *Int. J. Part. Ther.*, vol. 8, no. 2, pp. 1–16, Apr. 2021, doi: 10.14338/IJPT-20-00031.1.
- [23] A. R. Kagan and R. J. Schulz, "Proton-Beam Therapy for Prostate Cancer," *Cancer J.*, vol. 16, no. 5, 2010.
- [24] A. Santos, S. Penfold, P. Gorayski, and H. Le, "The Role of Hypofractionation in Proton Therapy," *Cancers*, vol. 14, no. 9, p. 2271, May 2022, doi: 10.3390/cancers14092271.
- [25] R. Baskar, K. A. Lee, R. Yeo, and K.-W. Yeoh, "Cancer and Radiation Therapy: Current Advances and Future Directions," *Int. J. Med. Sci.*, vol. 9, no. 3, pp. 193–199, Feb. 2012, doi: 10.7150/ijms.3635.
- [26] N. G. Burnet, S. J. Thomas, K. E. Burton, and S. J. Jefferies, "Defining the tumour and target volumes for radiotherapy," *Cancer Imaging*, vol. 4, no. 2, pp. 153–161, Oct. 2004, doi: 10.1102/1470-7330.2004.0054.
- [27] S. H. Benedict, "Review of Radiation Oncology Physics: A Handbook for Teachers and Students," *J. Appl. Clin. Med. Phys.*, vol. 5, no. 3, pp. 179–181, Jul. 2004, doi: 10.1120/jacmp.2021.25315.
- [28] "ICRU Report 50," 1993.
- [29] "ICRU Report 62," 1999.
- [30] "The International Commission on Radiation Units and Measurements (ICRU-83)," *J. ICRU*, vol. 10, no. 1, p. NP.2-NP, Apr. 2010, doi: 10.1093/jicru/ndq001.
- [31] International Commission on Radiological Protection, "The 2007 Recommendations of the International Commission on Radiological Protection," *ICRP 103*, vol. 37, no. 2–4, 2007.
- [32] M. J. LaRiviere, P. M. G. Santos, C. E. Hill-Kayser, and J. M. Metz, "Proton Therapy," *Hematol. Oncol. Clin. North Am.*, vol. 33, no. 6, pp. 989–1009, Dec. 2019, doi: 10.1016/j.hoc.2019.08.006.



- [33] J. H. L. Mott and J. M. Daniel, “Interactions of Electromagnetic Radiation and Subatomic Particles with Matter – Part 2,” *Clin. Oncol.*, vol. 33, no. 7, pp. 455–460, Jul. 2021, doi: 10.1016/j.clon.2021.02.005.
- [34] B. Gottschalk, “Radiotherapy Proton Interactions in Matter.” arXiv, Mar. 30, 2018. Accessed: Oct. 26, 2023. [Online]. Available: <http://arxiv.org/abs/1804.00022>
- [35] R. Mohan and D. Grosshans, “Proton Therapy – Present and Future,” *Adv. Drug Deliv. Rev.*, vol. 109, pp. 26–44, Jan. 2017, doi: 10.1016/j.addr.2016.11.006.
- [36] W. D. Newhauser and R. Zhang, “The physics of proton therapy,” *Phys. Med. Biol.*, vol. 60, no. 8, pp. R155–R209, Apr. 2015, doi: 10.1088/0031-9155/60/8/R155.
- [37] M. Hu, L. Jiang, X. Cui, J. Zhang, and J. Yu, “Proton beam therapy for cancer in the era of precision medicine,” *J. Hematol. Oncol.*, vol. 11, no. 1, p. 136, Dec. 2018, doi: 10.1186/s13045-018-0683-4.
- [38] W. Schlegel, T. Bortfeld, and A. Grosu, Eds., *New technologies in radiation oncology*. Berlin ; London: Springer, 2006.
- [39] P. Mandrillon, “CYCLOTRONS IN RADIOTHERAPY”.
- [40] Y. Ebara, H. Tsutsui, S. Nakajima, S. Hara, S. Nomura, K. Suga, J. Yoshida, K. Taki, H. Murata, N. Takahashi, A. Hashimoto, T. Sakemi, N. Kamiguchi, Y. Arakawa, T. Morie, T. Hirayama, H. Oda, S. Fujita, J. Kanakura, Y. Mikami, T. Tsurudome, T. Miyashita, and Y. Kumata, “First beam extraction from a superconducting azimuthally varying field cyclotron for proton therapy,” *Nucl. Instrum. Methods Phys. Res. Sect. Accel. Spectrometers Detect. Assoc. Equip.*, vol. 1056, p. 168629, Nov. 2023, doi: 10.1016/j.nima.2023.168629.
- [41] C. Baumgarten, “Cyclotron beam extraction by acceleration,” *J. Instrum.*, vol. 18, no. 03, p. P03029, Mar. 2023, doi: 10.1088/1748-0221/18/03/P03029.
- [42] T. Sato, Y. Iwamoto, S. Hashimoto, T. Ogawa, T. Furuta, S.-I. Abe, T. Kai, Y. Matsuya, N. Matsuda, Y. Hirata, T. Sekikawa, L. Yao, P.-E. Tsai, H. N. Ratliff, H. Iwase, Y. Sakaki, K. Sugihara, N. Shigyo, L. Sihver, and K. Niita, “Recent improvements of the particle and heavy ion transport code system – PHITS version 3.33,” *J. Nucl. Sci. Technol.*, vol. 61, no. 1, pp. 127–135, Jan. 2024, doi: 10.1080/00223131.2023.2275736.



- [43] “User’s Manual PHITS Ver 3.33.” Japan Atomic Energy Agency (JAEA), 2023.
- [44] C. H. Kim, Y. S. Yeom, N. Petoussi-Henss, M. Zankl, W. E. Bolch, C. Lee, C. Choi, T. T. Nguyen, K. Eckerman, H. S. Kim, M. C. Han, R. Qiu, B. S. Chung, H. Han, and B. Shin, *Adult mesh-type reference computational phantoms*. in Annals of the ICRP, no. volume 49, no. 3 (2020). London: SAGE, 2020.
- [45] R. M. Jr, C. Gesh, R. Pagh, R. Rucker, and R. W. Iii, “Compendium of Material Composition Data for Radiation Transport Modeling”.
- [46] T. Dang, “STANDARDIZED ORGAN AT RISK VOLUME FOR EXTERNAL BEAM RADIATION THERAPY IN PROSTATE CANCER AND ITS RELATIONSHIP TO VOLUMES DEFINED BY CLINICAL PRACTICE”.
- [47] L. B. Marks, E. D. Yorke, A. Jackson, R. K. Ten Haken, L. S. Constine, A. Eisbruch, S. M. Bentzen, J. Nam, and J. O. Deasy, “Use of Normal Tissue Complication Probability Models in the Clinic,” *Int. J. Radiat. Oncol.*, vol. 76, no. 3, pp. S10–S19, Mar. 2010, doi: 10.1016/j.ijrobp.2009.07.1754.
- [48] E. Samuel, S. Zaman, M. A. Bakar, and M. M. Fareed, “Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer,” *Discov. Oncol.*, vol. 15, no. 1, p. 27, Feb. 2024, doi: 10.1007/s12672-024-00876-7.
- [49] G. Chaput and L. Regnier, “Radiotherapy: Clinical pearls for primary care,” *Can. Fam. Physician*, vol. 67, no. 10, pp. 753–757, Oct. 2021, doi: 10.46747/cfp.6710753.

